EFFECT OF COMBINED NICOTINAMIDE, ACETYL-L-CARNITINE AND α-LIPOIC ACID ACTION ON SEPARATE LINKS OF CARBOHYDRATE METABOLISM UNDER EXPERIMENTAL TYPE 2 DIABETES

Iu. T. Sergiichuk, T. M. Tykhonenko, M. M. Guzyk, L. V. Yanitska, T. M. Kuchmerovska


DOI: http://dx.doi.org/10.30970/sbi.0803.391

Abstract


The effect of nicotinamide, acetyl-L-carnitine and α-lipoic acid on the separate links of carbohydrate metabolism in the brain, heart and liver of rats for type 2 diabetes it was investigated. Combined administration of nicotinamide, acetyl-L-carnitine and α-lipoic acid caused partial reduction of hyperglycemia in rats. By the action of investigated compounds activity of hexokinase and glucokinase, which were reduced under diabetes by 62 and 84 %, respectively, as compared to control was partially normalized. NAD contents in brain, heart and liver of diabetic rats were decreased by 46, 52 and 36 %, but were elevated by investigated compounds, especially in liver. It was found that ratio of free NAD/NADH and NADP/NADPH couples under diabetes were decreased in brain, liver and heart as compared to control. Redox-states in these tissues were significantly normalized by investigated compounds. Amino acid concentrations in blood serum of rats were altered and partially normalized by investigated compounds. Thus, combined effect of investigated compounds is more effective and can be used for the correction of carbohydrate metabolism and energetic state that were changed under type 2 diabetes.


Keywords


experimental type 2 diabetes, nicotinamide, acetyl-L-carnitine, α-li­poic acid, carbohydrate metabolism

References


1. Agius L. Glucokinase and molecular aspects of liver glycogen metabolism. Biochemical Journal, 2008; 414(1): 1-18.
https://doi.org/10.1042/BJ20080595
PMid:18651836

2. Bak J., Pedersen O. Glycogen synthase: characteristics and putative role in insulin insensitivity. Diabetes Annals, 1994; 8: 75-105.
https://doi.org/10.1016/1056-8727(94)90046-9

3. Bergmeyer H. Methods of Enzymatic Analysis. New York, London: Verlag Chemie, 1963. - 2300 p.

4. Bouché C., Serdy S., Kahn C. R. et al. The cellular fate of glucose and its relevance in type 2 diabetes. Endocrine Reviews, 2004; 25(5): 807-830.
https://doi.org/10.1210/er.2003-0026
PMid:15466941

5. Coleman M.D., Eason R.C., Bailey C.I. The therapeutic use of lipoic acid in diabetes: a current perspective. Enviroment Toxicology Pharmacology, 2001; 10: 167-173.
https://doi.org/10.1016/S1382-6689(01)00080-1

6. Coughlan K. A., Valentine R. J., Ruderman N. B. AMPK activation: a therapeutic target for type 2 diabetes? Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2014; 7: 241-253.
https://doi.org/10.2147/DMSO.S43731
PMid:25018645 PMCid:PMC4075959

7. Danforth W. H. Glycogen synthetase activity in skeletal muscle. The Journal of Biological Chemistry, 1965; 240(2): 588-593.

8. Delarue J., Magnan C. Free fatty acids and insulin resistance. Current Opinion in Clinical Nutrution and Metabolic Care, 2007; 10(2): 142-148.
https://doi.org/10.1097/MCO.0b013e328042ba90
PMid:17285001

9. Drel V.R., Pacher P., Stavniichuk R. et al. Poly(ADP-ribose)polymerase inhibition counteracts renal hypertrophy and multiple manifestations of peripheral neuropathy in diabetic Akita mice. International Journal of Molecular Medicine, 2011; 4(28): 629-635.

10. Eprinsev A.T., Shevchenko M.Yu., Popov V.N. Carbohydrate metabolism in the liver of rats in food deprivation and experimental diabetes. Biology Bulletins, 2008; 35(1): 99-101.
https://doi.org/10.1134/S1062359008010159

11. Fahien L., MacDonald J. M. The succinate mechanism of insulin release. Diabetes, 2002; 51: 2669-2676.
https://doi.org/10.2337/diabetes.51.9.2669
PMid:12196457

12. Ferrero E., Buono N. L., Horenstein A. L. et al. The ADP-ribosyl cyclases - the current evolutionary state of the ARCs. Frontiers in Bioscience, 2014; 19: 986-1002.
https://doi.org/10.2741/4262

13. Forbes J. M., Cooper M. E. Mechanisms of diabetic complications. Physiology Reviews, 2013; 93: 137-188.
https://doi.org/10.1152/physrev.00045.2011
PMid:23303908

14. Giacco F., Brownlee M. Oxidative stress and diabetic complications. Circulation Research, 2010; 107: 1058-1070.
https://doi.org/10.1161/CIRCRESAHA.110.223545
PMid:21030723 PMCid:PMC2996922

15. Guse A. H. Biochemistry, biology, and pharmacology of cyclic adenosine diphosphoribose (cADPR). Current Medical Chemistry, 2004; 11(7): 847-855.
https://doi.org/10.2174/0929867043455602

16. Hemmings S.J., Spafford D. Neonatal STZ model of type II diabetes mellitus in the Fischer 344 rat: characteristics and assessment of the status of the hepatic adrenergic receptors. The International Journal of Biochemistry & Cell Biology, 2000; 32: 905-919.
https://doi.org/10.1016/S1357-2725(00)00019-4

17. Imai S., Kiess W. Therapeutic potential of SIRT1 and NAMPT-mediated NAD biosynthesis in type 2 diabetes. Frontiers Bioscienсе (Landmark Ed), 2009; 14: 2983-2995.
https://doi.org/10.2741/3428

18. Kathirvel E., Kengathevy M., French S.W. et al. Acetyl-l-carnitine and lipoic acid improve mitochondrial abnormalities and serum levels of liver enzymes in a mouse model of nonalcoholic fatty liver disease. Nutrition Research, 2013; 33(11): 932-941.
https://doi.org/10.1016/j.nutres.2013.08.001
PMid:24176233

19. Kuchmerovska Т., Shymanskyy I., Donchenko G. et al. Poly-ADP- ribosylation enhancement in brain cells nuclei is associated with diabetic neuropathy. Journal of Diabetes and Its Complications, 2004; 18(4):198-204.
https://doi.org/10.1016/S1056-8727(03)00039-4

20. Lacroix I., Li-Chan E. Overview of food products and dietary constituents with antidiabetic properties and their putative mechanisms of action: A natural approach to complement pharmacotherapy in the management of diabetes. Molecular Nutrition & Food Research, 2014; 58(1): 61-78.
https://doi.org/10.1002/mnfr.201300223
PMid:23943383

21. Miyata Y., Shimomura I. Metabolic flexibility and carnitine flux: The role of carnitine acyltransferase in glucose homeostasis. Journal of Diabetes Investigation, 2013; 4(3): 247-249.
https://doi.org/10.1111/jdi.12064
PMid:24843661 PMCid:PMC4015659

22. Morifuji M., Sakai K., Sanbongi C. et al. Dietary whey protein increases liver and skeletal muscle glycogen levels in exercise-trained rats. British Journal of Nutrition, 2005; 93: 439-445.
https://doi.org/10.1079/BJN20051373
PMid:15946405

23. Moses R.G. Combination therapy for patients with type 2 diabetes: repaglinide in сombination with metformin. Expert Review of Endocrinology and Metabolism, 2010; 5(3): 331-342.
https://doi.org/10.1586/eem.10.17
PMid:30861688

24. Muecklera M., Thorens B. The SLC2 (GLUT) family of membrane transporters. Molecular Aspects of Medicine, 2013; 34(2-3): 121-138.
https://doi.org/10.1016/j.mam.2012.07.001
PMid:23506862 PMCid:PMC4104978

25. Ribas G.S., Vargas C.R, Wajner M. L-carnitine supplementation as a potential antioxidant therapy for inherited neurometabolic disorders. Gene, 2014; 533(2): 469-476.
https://doi.org/10.1016/j.gene.2013.10.017
PMid:24148561

26. Ringseis R., Keller J. Role of carnitine in the regulation of glucose homeostasis and insulin sensitivity: evidence from in vivo and in vitro studies with carnitine supplementation and carnitine deficiency. European Journal of Nutrition, 2012; 1: 1-18.
https://doi.org/10.1007/s00394-011-0284-2
PMid:22134503

27. Shaw J.E., Sicree R.A., Zimmet P.Z. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Research and Clinical Practice, 2010; 87: 4-14.
https://doi.org/10.1016/j.diabres.2009.10.007
PMid:19896746

28. Stahl W., Sies H. Antioxidant defence: Vitamins E and C and carothenoids. Diabetes, 1997; 46(2): 14-18.
https://doi.org/10.2337/diab.46.2.S14
PMid:9285493

29. Thirunavukkarasu V., Nandhini A., Anuradha C.V. Lipoic acid improves glucose utilisation and prevents protein glycation and AGE formation. Pharmazie, 2005; 60(10): 772-775.

30. Udupa A., Nahar P., Shah S. et al. A comparative study of effects of omega-3 fatty acids, alpha lipoic acid and vitamin E in type 2 diabetes mellitus. Annals of Medical and Health Science Research, 2013; 3: 442-446.
https://doi.org/10.4103/2141-9248.117954
PMid:24116330 PMCid:PMC3793456

31. Wilson J.E. Isozymes of mammalian hexokinase structure, subcellular localization and metabolic function. The Journal of Experimental Biology, 2003; 206: 2049-2057.
https://doi.org/10.1242/jeb.00241
PMid:12756287

32. Yanga S.J., Mook Choib J., Kim L. et al. Nicotinamide improves glucose metabolism and affects the hepatic NAD-sirtuin pathway in a rodent model of obesity and type 2 diabetes. The Journal of Nutritional Biochemistry, 2014; 25(1): 66-72.
https://doi.org/10.1016/j.jnutbio.2013.09.004
PMid:24314867

33. Ying W. NAD+/NADH and NADP+/NADPH in cellular functions and cell death: regulation and biological consequences. Antioxid Redox Signal, 2008; 10(2):179-206.
https://doi.org/10.1089/ars.2007.1672
PMid:18020963

34. Yoshino J., Mills K. F., Yoon M. J. et al. Nicotinamide mononucleotide, a key NAD+ intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice. Cell Metabolism, 2011; 14(4): 528-536.
https://doi.org/10.1016/j.cmet.2011.08.014
PMid:21982712 PMCid:PMC3204926


Refbacks

  • There are currently no refbacks.


Copyright (c) 2014 Studia biologica

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.